Larimar Therapeutics, Inc.
NASDAQ:LRMR
3.78 (USD) • At close December 24, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.311 | 0.272 | 0.326 | 0.155 | 0.078 | 0.261 | 0.188 | 0.212 | 0.07 | 0 | 0.012 | 0.011 | 0.004 |
| Gross Profit
| -0.311 | -0.272 | -0.326 | -0.155 | -0.078 | -0.261 | -0.188 | -0.212 | -0.07 | 0 | -0.012 | -0.011 | -0.004 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 27.359 | 24.25 | 38.396 | 31.407 | 20.79 | 49.529 | 41.739 | 39.774 | 54.618 | 27.391 | 9.561 | 11.544 | 11.403 |
| General & Administrative Expenses
| 14.088 | 12.276 | 12.069 | 11.397 | 2.424 | 1.517 | 12.16 | 18.289 | 19.195 | 8.141 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 12.93 | -0.212 | -1.153 | -0.07 | 0 | 0 | 0 | 0 |
| SG&A
| 14.088 | 12.276 | 12.069 | 11.397 | 2.424 | 12.932 | 11.948 | 17.136 | 19.125 | 8.141 | 4.207 | 2.236 | 1.747 |
| Other Expenses
| 0 | 1.171 | -0.171 | 0.322 | 0.082 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 41.758 | 36.526 | 50.465 | 42.804 | 23.214 | 62.461 | 53.687 | 56.91 | 73.743 | 35.532 | 13.768 | 13.78 | 13.15 |
| Operating Income
| -41.758 | -36.526 | -50.465 | -42.804 | -23.214 | -62.722 | -53.875 | -57.122 | -73.813 | -35.532 | -13.78 | -13.791 | -13.154 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 4.809 | 1.171 | -0.171 | 0.322 | 0.082 | -0.246 | 0.947 | -1.056 | -0.473 | -1.038 | -0.247 | -0.089 | -0.003 |
| Income Before Tax
| -36.949 | -35.355 | -50.636 | -42.482 | -23.132 | -62.968 | -52.928 | -58.178 | -74.286 | -36.57 | -14.027 | -13.88 | -13.157 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -1.171 | -0.326 | -0.155 | -0.094 | -1.6 | -0.9 | -0.3 | -0.946 | 0 | 0 | 0 | 0 |
| Net Income
| -36.949 | -34.184 | -50.31 | -42.327 | -23.132 | -61.368 | -52.028 | -57.878 | -74.286 | -36.57 | -14.027 | -13.88 | -13.157 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.84 | -1.33 | -2.93 | -3.56 | -2.51 | -22.85 | -22.76 | -25.44 | -33.32 | -15.14 | -6.54 | -6.4 | -6.07 |
| EPS Diluted
| -0.84 | -1.33 | -2.93 | -3.56 | -2.51 | -22.85 | -22.76 | -25.44 | -33.32 | -15.14 | -6.54 | -6.4 | -6.07 |
| EBITDA
| -41.447 | -35.083 | -50.139 | -42.649 | -23.136 | -60.809 | -52.575 | -57.437 | -73.41 | -35.532 | -14.015 | -13.772 | -13.153 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |